Navigation Links
Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
Date:10/29/2010

s issued by Angiotech or to include such information in documents required to be filed with the applicable United States or Canadian securities regulatory authorities or otherwise make such information publicly available.

The projections and other forward looking financial information found herein were not, when made, and are not, historical facts but are forward looking statements about the objectives, strategies, financial conditions, results of operations and businesses of Angiotech and its subsidiaries and are subject to important risks, uncertainties and assumptions.  The forward looking statements and projections set out in this press release are, in the case of Angiotech's Base Medical Products and Proprietary Medical Products businesses, based upon Angiotech's reasonable estimates, assumptions and expectations about these businesses and the markets in which Angiotech operates at the time such information was prepared, or in the case of Angiotech's Royalty business, are derived based upon certain publicly available information, including analyst reports and other sources, regarding expectations for certain products, in particular for sales of paclitaxel-eluting stents by certain of our partners from which we derive or expect to derive royalty revenue pursuant to intellectual property licensing agreements with those partners.  In each case, such projections or forward looking statements are subject to significant business, economic, competitive and other uncertainties and contingencies (including those set out under the heading "Risk Factors" contained in Angiotech's Annual Report on Form 10-K for the year ended December 31, 2009, as updated in Angiotech's most recent Form 10-Q and Management's Discussion and Analysis for the six months ended June 30, 2010), which are beyond Angiotech's or our partners' control.

In addition, forward looking statements reflect numerous assumptions by Angiotech and industry analysts with respect to fu
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
2. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
3. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
4. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
5. Angiotech Pharmaceuticals announces time change of conference call and webcast
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
8. Angiotech announces positive results from Bio-Seal(TM) clinical study
9. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
10. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
11. Angiotech announces date of annual general meeting of shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... Jan. 14, 2014 As pet owners drew up their lists ... them wrote: "Take better care of my furry companion." Nowadays there ... and top-brand carrying cases to take the little canine or feline ... feel compelled to buy some pricey toys at the pet store. ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... Orange, CA (PRWEB) January 14, 2014 Kerr ... a 10-minute video and additional how-to information about dual arch ... Great Restorations with Dual Arch Impressions,” the blog entry serves ... the technique and houses a step-by-step demonstration by Dr. David ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... to Additional Capital Will Enable Revenue Growth, ... Bulletin Board: BLFS), a leading developer and marketer ... tissues, and organs, today announced that it reached ... to increase the Company,s,existing credit facility from $5 ...
... that NanoBio,s nanoemulsion technology is effective when ... used in therapeutic applications and vaccines, ANN ... it will present compelling new data in nine presentations ... programs,in onychomycosis, herpes labialis, cystic fibrosis and an intra-nasal,influenza ...
... NxStage Medical,Inc. (Nasdaq: NXTM ), a ... its Medisystems Division has signed a,long-term product supply ... provider of dialysis services in the United States. ... the Streamline(TM) airless,blood tubing set as well as ...
Cached Biology Technology:BioLife Solutions Credit Facility Increased to $9 Million 2NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008 2NxStage Announces Streamline(TM) Blood Tubing Set Supply Agreement with Renal Advantage Inc. 2NxStage Announces Streamline(TM) Blood Tubing Set Supply Agreement with Renal Advantage Inc. 3
(Date:7/9/2014)... pivotal in the development of cancer, viral infection and ... question about one of the most widely-researched proteins in ... of thousands of research papers and millions of pounds ... in Professor Sir Philip Cohen,s laboratory at the University ... is activated. The results are published today ...
(Date:7/9/2014)... ability to switch out one gene for another in ... from science fiction to reality within this decade. As ... promise--the hope of fixing disease-causing genes in humans, for ... scientists have put one of those concerns to rest: ... overall occurrence of mutations in the cells. The new ...
(Date:7/9/2014)... geographic ranges in which animals can be found, concern ... Does an increased range for a host mean new ... says a team of UC Santa Barbara scientists, including ... published in the Journal of Biogeography , Hechinger, ... opposite may happen: Hosts may actually lose their parasites ...
Breaking Biology News(10 mins):Research reveals how key controller protein is switched on 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Not at home on the range 2Not at home on the range 3Not at home on the range 4
... the humble honey bee, researchers at the University of ... understanding the molecular basis of social behavior in humans. ... a model system for social behavior," said Saurabh (pronounced ... affiliate of the university's Institute for Genomic Biology. Using ...
... Children with cancer who suffer hearing loss due to the ... get their hearing back through pharmacological and gene therapy, thanks ... Research Hospital. Mice with a variety of genetic mutations that ... understand age-related hearing loss in adults, as well as hearing ...
... cause of blindness in western society, say experts at The ... eye instrument, they have launched a study to see if ... also explain why the 77-year-old sailor has no need for ... and broccoli are rich in a chemical called lutein, which, ...
Cached Biology News:Honey bee genome holds clues to social behavior 2St. Jude finds clues to hearing loss from chemotherapy 2Why Popeye only has eyes for spinach 2
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Assay Diluent 500 mls...
Mouse monoclonal [4C4] to Y14 ( Abpromise for all tested applications). entrezGeneID: 9939 SwissProtID: Q9Y5S9...
Biology Products: